- Home
- BIDU vs CANF Comparison
BIDU vs CANF Comparison
Compare BIDU & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIDU | CANF |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4B | 6.7M |
| IPO Year | 2005 | 2011 |
Fundamental Metrics
Financial Performance| Metric | BIDU | CANF |
|---|---|---|
| Price | $92.21 | $2.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 2 |
| Target Price | ★ $154.38 | $50.00 |
| AVG Volume (30 Days) | ★ 2.2M | 207.7K |
| Earning Date | 05-18-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.11 | $2,715,455.50 |
| Revenue Next Year | $7.44 | $101.06 |
| P/E Ratio | $42.45 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $88.23 | $0.17 |
| 52 Week High | $165.30 | $10.40 |
Technical Indicators
Market Signals| Indicator | BIDU | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 32.90 |
| Support Level | $89.60 | $2.16 |
| Resistance Level | $99.64 | $2.39 |
| Average True Range (ATR) | 1.80 | 0.12 |
| MACD | 0.30 | -0.02 |
| Stochastic Oscillator | 37.16 | 7.96 |
Price Performance
Historical ComparisonAbout BIDU Baidu Inc. ADS
Most of Baidu's revenue comes from Baidu core, with the rest coming from video-streaming subsidiary iQiyi. The firm's main businesses include online marketing services from its search engine, AI cloud infrastructure, AI applications, AI marketing, and autonomous driving.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.